Physician profile
Farah Najamuddin
NPI 1063499309
$191.99
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $26.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $51.99 | 2019-2021 | |
| Pfizer INC. | $26.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.48 | 2019 | |
| Novo Nordisk INC | $16.84 | 2019 | |
| Lilly USA, LLC | $15.22 | 2019 | |
| Glaxosmithkline, LLC. | $13.23 | 2019 | |
| Amarin Pharma, INC. | $13.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Najamuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.